Importantly, those SMR peptides abrogated the mortalin-mediated ability of breast cancer cells to release extracellular vesicles (exosomes), thereby blocking the mortalin-associated protection of the cancer cells from complement-dependent cell death [231]. Here, HSPA9 is linked to breast carcinoma.